NEW YORK ( TheStreet) -- Pharmaceutical and Biotech ETFs are prominent gainers on Monday morning as M&A deals appear poised to pick up in the sector. Speculation that Sanofi Aventis (SNY) is looking to acquire Genzyme (GENZ) sent the stock of Genzyme soaring on Friday. Word on the street is that other large pharmaceutical majors such as GlaxoSmithKline (GSK) and Johnson&Johnson (JNJ)may also join the race.
SPDR S&P Biotech Fund
(XBI) is rising 4% on Monday morning. Its top holdings include
(REGN), up 5.4% and
(BIIB), up 4.9%. Other biotech ETFs including
iShares Nasdaq Biotechnology
(BBH) also gained smartly.
More on Biotech
13 Drugs Facing FDA Approval
PowerShares Dynamic Pharmaceuticals (PJP) is up 2% on Monday forenoon trading.Other ETF gainers include the iShares Dow Jones Transportation Average (IYT). The ETF is heading higher after Fedex (FDX) raised its full-year outlook. Homebuilder ETFs also rebounded on Monday after new homes sales in June showed strong monthly gains of 23.6%. The SPDR Homebuilders ETF (XHB) is up 2.1%. -- Reported by Shanthi Venkataraman in New York. Follow TheStreet.com on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV